News

Burris, who will join the company in this capacity on 3 January 2011, is currently a member of the board of directors of OncoGenex. Most recently, Burris worked

Nutrition 21, headquartered in Purchase, NY, is a nutritional bioscience company and holds over 60 issued and pending patents for dietary supplement ingredients, including chromium picolinate and combinations

The Eramune 01 study is an international, multicenter, randomised, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV-infected patients with long-term viral suppression. Eramune 01 will use

Pfizer’s anti-TNF-alpha Nanobody, ATN-103, is currently in a Phase II study in patients with rheumatoid arthritis (RA) and it has completed recruitment for the Phase II study. Ablynx

Crean, in the new role is expected to be responsible for all of Aqua’s acquisition, licensing and corporate initiatives. Crean joins Aqua following a senior director for Business

According to TB Alliance, the novel three-drug combination shows promise to treat both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and alter the course of the TB pandemic by

The grant covers Merrimack’s three clinical stage cancer programs, MM-121, a new, first-in-class ErbB3 (HER3) antagonist, MM-111, a new bi-specific antibody targeting ErbB2/ErbB3 (HER2/HER3) and MM-398, a nanoliposomal

The study results showed the ‘CEL-2000-DepoVax’ combination considerably lessened the symptoms and slowed the progression of RA in the animal model with a single dose. The two companies

Endo said that, the new formulation of long-acting Oxymorphone designed to be crush-resistant, is a semi-synthetic opioid analgesic intended for the treatment of moderate to severe chronic pain